Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) EBT (2018 - 2025)

Dna X filings provide 8 years of EBT readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, EBT fell 61.07% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.0 million, a 175.93% decrease, with the full-year FY2025 number at -$8.0 million, down 175.93% from a year prior.
  • EBT hit $3.5 million in Q4 2025 for Dna X, up from -$4.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $12.8 million in Q4 2022 to a low of -$11.8 million in Q4 2021.
  • Median EBT over the past 5 years was -$2.6 million (2024), compared with a mean of -$2.5 million.
  • The widest YoY moves for EBT: up 804.13% in 2024, down 1232.36% in 2024.
  • Dna X's EBT stood at -$11.8 million in 2021, then surged by 208.86% to $12.8 million in 2022, then plummeted by 109.82% to -$1.3 million in 2023, then surged by 804.13% to $8.9 million in 2024, then crashed by 61.07% to $3.5 million in 2025.
  • The last three reported values for EBT were $3.5 million (Q4 2025), -$4.7 million (Q3 2025), and -$7.3 million (Q2 2025) per Business Quant data.